NZ724544A - Treatment of brain cancer - Google Patents

Treatment of brain cancer

Info

Publication number
NZ724544A
NZ724544A NZ724544A NZ72454413A NZ724544A NZ 724544 A NZ724544 A NZ 724544A NZ 724544 A NZ724544 A NZ 724544A NZ 72454413 A NZ72454413 A NZ 72454413A NZ 724544 A NZ724544 A NZ 724544A
Authority
NZ
New Zealand
Prior art keywords
brain cancer
treatment
dihydrooxazol
triazolo
quinazoline
Prior art date
Application number
NZ724544A
Other languages
English (en)
Inventor
Patrice Lee
Shannon Winski
Kevin Koch
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ724544(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Priority to NZ74161513A priority Critical patent/NZ741615A/en
Publication of NZ724544A publication Critical patent/NZ724544A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NZ724544A 2012-03-23 2013-03-25 Treatment of brain cancer NZ724544A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ74161513A NZ741615A (en) 2012-03-23 2013-03-25 Treatment of brain cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261615082P 2012-03-23 2012-03-23
NZ630843A NZ630843A (en) 2012-03-23 2013-03-25 Treatment of brain cancer

Publications (1)

Publication Number Publication Date
NZ724544A true NZ724544A (en) 2018-05-25

Family

ID=48048296

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ724544A NZ724544A (en) 2012-03-23 2013-03-25 Treatment of brain cancer
NZ74161513A NZ741615A (en) 2012-03-23 2013-03-25 Treatment of brain cancer
NZ630843A NZ630843A (en) 2012-03-23 2013-03-25 Treatment of brain cancer
NZ756264A NZ756264A (en) 2012-03-23 2013-03-25 Treatment of brain cancer

Family Applications After (3)

Application Number Title Priority Date Filing Date
NZ74161513A NZ741615A (en) 2012-03-23 2013-03-25 Treatment of brain cancer
NZ630843A NZ630843A (en) 2012-03-23 2013-03-25 Treatment of brain cancer
NZ756264A NZ756264A (en) 2012-03-23 2013-03-25 Treatment of brain cancer

Country Status (30)

Country Link
US (3) US20150110780A1 (cg-RX-API-DMAC7.html)
EP (4) EP3400943B1 (cg-RX-API-DMAC7.html)
JP (6) JP2015514075A (cg-RX-API-DMAC7.html)
KR (3) KR102160462B1 (cg-RX-API-DMAC7.html)
CN (2) CN109223791A (cg-RX-API-DMAC7.html)
AU (4) AU2013234921A1 (cg-RX-API-DMAC7.html)
CA (1) CA2867723C (cg-RX-API-DMAC7.html)
CL (1) CL2014002497A1 (cg-RX-API-DMAC7.html)
CO (1) CO7071139A2 (cg-RX-API-DMAC7.html)
CY (2) CY1120204T1 (cg-RX-API-DMAC7.html)
DK (2) DK2827900T3 (cg-RX-API-DMAC7.html)
ES (2) ES2673165T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180659T1 (cg-RX-API-DMAC7.html)
HU (2) HUE053156T2 (cg-RX-API-DMAC7.html)
IL (3) IL234627B (cg-RX-API-DMAC7.html)
LT (1) LT2827900T (cg-RX-API-DMAC7.html)
MX (1) MX354024B (cg-RX-API-DMAC7.html)
MY (2) MY174883A (cg-RX-API-DMAC7.html)
NZ (4) NZ724544A (cg-RX-API-DMAC7.html)
PH (2) PH12021550360A1 (cg-RX-API-DMAC7.html)
PL (2) PL2827900T3 (cg-RX-API-DMAC7.html)
PT (2) PT2827900T (cg-RX-API-DMAC7.html)
RS (1) RS57140B1 (cg-RX-API-DMAC7.html)
RU (2) RU2018138976A (cg-RX-API-DMAC7.html)
SG (1) SG11201405954YA (cg-RX-API-DMAC7.html)
SI (2) SI2827900T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800251T1 (cg-RX-API-DMAC7.html)
TR (1) TR201808450T4 (cg-RX-API-DMAC7.html)
UA (1) UA122044C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013142875A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102000312B1 (ko) 2011-10-14 2019-07-15 어레이 바이오파마 인크. Erb2 (her2) 저해제의 고체 분산물
US9168254B2 (en) 2011-10-14 2015-10-27 Array Biopharma Inc. Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them
RS57140B1 (sr) 2012-03-23 2018-07-31 Array Biopharma Inc Amorfna čvrsta disperzija za korišćenje u lečenju raka mozga
WO2018165015A1 (en) * 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
CN112566665A (zh) * 2018-04-09 2021-03-26 莫舍·吉拉迪 用TTFields和Aurora激酶抑制剂治疗肿瘤
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
IL330104A (en) 2019-03-11 2026-08-01 Deciphera Pharmaceuticals Llc Crystalline forms of rifatinib
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
US20250387380A1 (en) * 2019-12-30 2025-12-25 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
US20020137731A1 (en) 2000-05-30 2002-09-26 Gewirtz David A. Combination of radiation and vitamin D3 analogs for the treatment of cancer
JP4828421B2 (ja) 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
BRPI0511754A (pt) 2004-06-03 2008-01-02 Smithkline Beechman Cork Ltd uso de um composto ou sais ou solvatos do mesmo
CN1989112A (zh) * 2004-06-03 2007-06-27 史密丝克莱恩比彻姆(科克)有限公司 癌症治疗方法
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
CA2637166A1 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies for treating cancer
US20120052061A1 (en) * 2007-09-24 2012-03-01 Tragara Pharmaceuticals Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
NZ587706A (en) * 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
KR102000312B1 (ko) 2011-10-14 2019-07-15 어레이 바이오파마 인크. Erb2 (her2) 저해제의 고체 분산물
US9168254B2 (en) * 2011-10-14 2015-10-27 Array Biopharma Inc. Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them
RS57140B1 (sr) 2012-03-23 2018-07-31 Array Biopharma Inc Amorfna čvrsta disperzija za korišćenje u lečenju raka mozga

Also Published As

Publication number Publication date
KR20140139009A (ko) 2014-12-04
MY174883A (en) 2020-05-20
RS57140B1 (sr) 2018-07-31
IL269205A (en) 2019-11-28
PH12021550360A1 (en) 2023-04-03
EP3400943A1 (en) 2018-11-14
RU2672575C2 (ru) 2018-11-16
EP2827900A1 (en) 2015-01-28
US20190255051A1 (en) 2019-08-22
HK1206276A1 (en) 2016-01-08
AU2019203618A1 (en) 2019-06-13
PT2827900T (pt) 2018-06-14
DK2827900T3 (en) 2018-05-07
CA2867723A1 (en) 2013-09-26
EP4252855A3 (en) 2023-11-15
SI3400943T1 (sl) 2021-03-31
MX2014011437A (es) 2014-11-10
JP2015514075A (ja) 2015-05-18
LT2827900T (lt) 2018-05-10
CY1120204T1 (el) 2018-12-12
DK3400943T3 (da) 2021-02-08
AU2017272232C1 (en) 2019-08-15
CN104203279B (zh) 2018-10-30
JP2022190126A (ja) 2022-12-22
NZ630843A (en) 2017-01-27
CO7071139A2 (es) 2014-09-30
PT3400943T (pt) 2021-02-02
AU2017272232B2 (en) 2019-02-28
CA2867723C (en) 2022-11-08
KR20210131426A (ko) 2021-11-02
EP3400943B1 (en) 2020-12-02
HRP20180659T1 (hr) 2018-06-01
WO2013142875A1 (en) 2013-09-26
MY202114A (en) 2024-04-04
PL2827900T3 (pl) 2018-08-31
CY1123837T1 (el) 2022-05-27
US20150110780A1 (en) 2015-04-23
KR102160462B1 (ko) 2020-09-28
AU2021261849A1 (en) 2021-12-02
NZ741615A (en) 2019-10-25
RU2018138976A3 (cg-RX-API-DMAC7.html) 2022-04-08
RU2018138976A (ru) 2018-12-06
ES2673165T3 (es) 2018-06-20
CL2014002497A1 (es) 2014-11-14
KR102317166B1 (ko) 2021-10-26
AU2017272232A1 (en) 2018-01-04
JP2024019526A (ja) 2024-02-09
KR102490961B1 (ko) 2023-01-19
NZ756264A (en) 2022-09-30
JP2017141302A (ja) 2017-08-17
RU2014142700A (ru) 2016-05-20
HUE053156T2 (hu) 2021-06-28
ES2855142T3 (es) 2021-09-23
IL261659A (en) 2018-10-31
US20230190749A1 (en) 2023-06-22
EP2827900B1 (en) 2018-03-21
SG11201405954YA (en) 2014-10-30
SMT201800251T1 (it) 2018-07-17
HUE037966T2 (hu) 2018-09-28
US11504370B2 (en) 2022-11-22
JP6898960B2 (ja) 2021-07-07
JP7404485B2 (ja) 2023-12-25
CN104203279A (zh) 2014-12-10
PL3400943T3 (pl) 2021-06-14
CN109223791A (zh) 2019-01-18
PH12014502032A1 (en) 2014-11-24
UA122044C2 (uk) 2020-09-10
AU2019203618B2 (en) 2021-08-05
KR20200115656A (ko) 2020-10-07
EP3842044A1 (en) 2021-06-30
MX354024B (es) 2018-02-08
JP2021178820A (ja) 2021-11-18
SI2827900T1 (en) 2018-06-29
TR201808450T4 (tr) 2018-07-23
JP2019081792A (ja) 2019-05-30
AU2013234921A1 (en) 2014-10-02
IL269205B (en) 2020-06-30
EP4252855A2 (en) 2023-10-04
IL234627B (en) 2018-10-31

Similar Documents

Publication Publication Date Title
EP4252855A3 (en) Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
CL2014000930A1 (es) Dispersion solida que comprende n4-(4-([1,2,4]triazolo-[1,5-a]piridina-7-iloxi)-3-metilfenil)-n6-(4,4-dimetil-4,5-dihidrooxazol-2-il)quinazolina-4,6-diamina y un polimero de dispersion; proceso de preparacion; composicion farmaceutica; uso en el tratamiento del cancer de mama, gastrico, colorectal, pancreatico, entre otros.
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
GB201205669D0 (en) Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
PH12015501965B1 (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
SI2694072T1 (en) A combination of an AKT-inhibiting compound and abiraterone for use in therapeutic treatment
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
TN2015000170A1 (en) Tec family kinase inhibitor adjuvant therapy
TN2012000067A1 (en) Oxazine derivatives and their use in the treatment of neurological disorders
MX354210B (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
UA117590C2 (uk) ПОХІДНІ ПІРОЛО[3,2-d]ПІРИМІДИНУ ДЛЯ ЛІКУВАННЯ ВІРУСНИХ ІНФЕКЦІЙ ТА ІНШИХ ЗАХВОРЮВАНЬ
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
CL2014000932A1 (es) Polimorfos cristalinos de n4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)-n6-(4,4-dimetil-4,5-dihidrooxazol-2-il)quinazolina-4,6-diamina, inhibidores de erbb2; procedimiento para prepararlos; composicion farmaceutica; metodo para prevenir o tratar; y uso para tratar el cancer de mama, gastrico y biliar, entre otros.
MX368625B (es) Derivados de tieno[3,2-d]pirimidinas para el tratamiento de infecciones virales.
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
GB201115977D0 (en) Neurodevelopmental disorders
NZ631362A (en) Arry-520 for use in treating cancer in a patient with low aag
UA111383C2 (uk) Тверда дисперсія

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 MAR 2020 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20181129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2022 BY THOMSON REUTERS

Effective date: 20210206

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2023 BY THOMSON REUTERS

Effective date: 20220302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2024 BY THOMSON REUTERS

Effective date: 20230201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2025 BY THOMSON REUTERS

Effective date: 20240201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2026 BY THOMSON REUTERS

Effective date: 20250203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 MAR 2027 BY THOMSON REUTERS

Effective date: 20260202